雷贝拉唑联用莫沙必利治疗糖尿病合并慢性胃炎效果观察
2018-12-10孙瑜
孙瑜
[摘要] 目的 探讨雷贝拉唑联用莫沙必利治疗糖尿病合并慢性胃炎的效果。方法 选取该院2017年5月—2018年5月收治的糖尿病合并慢性胃炎患者110例,随机分为2组,各55例,对照组给予雷贝拉唑,观察组在对照组的基础上联用莫沙必利。 结果 观察组总有效率为94.5%,显著优于对照组78.2%,差异有统计学意义(P<0.05);观察组FPG(5.6±0.8)mmol/L、症状消失时间(7.8±2.1)d明显优于对照组,差异有统计学意义(P<0.05)。 结论 雷贝拉唑联用莫沙必利治疗糖尿病合并慢性胃炎效果显著,能有效改善患者临床症状,值得应用。
[关键词] 雷贝拉唑;莫沙必利;糖尿病;慢性胃炎
[中图分类号] R587.1 [文献标识码] A [文章编号] 1672-4062(2018)08(a)-0089-02
Observation on Effect of Rabeprazole Combined with Mosapride in Treatment of Diabetes Combined with Chronic Gastritis
SUN Yu
Digestive System Department, Changchun Central Hospital, Changchun, Jilin Province, 130000 China
[Abstract] Objective To study the effect of rabeprazole combined with mosapride in treatment of diabetes combined with chronic gastritis. Methods 110 cases of patients with diabetes combined with chronic gastritis admitted and treated in our hospital from May 2017 to May 2018 were selected and randomly divided into two groups with 55 cases in each, the control group were treated with rabeprazole, while the observation group were treated with rabeprazole combined with mosapride. Results The total treatment effective rate in the observation group was obviously better than that in the control group (94.5% vs 78.2%),the difference was statistically significant(P<0.05), and the FPG, symptom disappearance time in the observation group were respectively(5.6±0.8)mmol/L and (7.8±2.1)d, which were obviously better than those in the control group,the difference was statistically significant(P<0.05). Conclusion The effect of rabeprazole combined with mosapride in treatment of diabetes combined with chronic gastritis is obvious, which can effectively improve the clinical symptoms of patients, and it is worth application.
[Key words] Rabeprazole; Mosapride; Diabetes; Chronic gastritis
近年來,糖尿病的“爆发式”增长,已成为影响我国人群健康和生活质量的主要疾病。患者长期存在的高血糖,易引起各种组织、血管、神经的慢性损害,导致各种并发症与合并症的发生[1]。慢性胃炎是临床常见的消化道疾病,是不同病因引起的慢性胃黏膜炎性病变,其发生率在各种消化道疾病中居首位。有关报道显示[2],我国肠胃病患者约1.2亿,其中慢性胃炎发病率占30%~45%。当糖尿病合并慢性胃炎时,不仅对胃黏膜的修复和幽门螺旋菌的根除造成影响,还可引起血糖控制不良。为探讨有效的治疗方法,该对2017年5月—2018年5月收治的55例糖尿病合并慢性胃炎患者采用雷贝拉唑联用莫沙必利治疗,取得满意效果,现报道如下。
1 资料与方法
1.1 一般资料
选取该院收治的糖尿病合并慢性胃炎患者110例为观察对象,随机将患者分为2组,各55例,观察组男34例,女21例,年龄37~74岁,平均年龄(56.3±2.1)岁,糖尿病病程3~17年,平均(9.9±1.5)年,慢性胃炎病程3~8年,平均病程(4.6±1.0)年;对照组男37例,女18例,年龄36~72岁,平均年龄(57.6±1.8)岁,糖尿病病程3~15年,平均病程(9.4±1.7)年,慢性胃炎病程3~8年,平均病程(4.3±0.8)年。……
